Zacks Investment Research on MSN2d
Merck Inks $2B Licensing Deal With Chinese Biotech for Oral Heart Drug
Merck MRK announced that it has entered into an exclusive licensing deal with China-based Jiangsu Hengrui Pharmaceuticals ...
Zacks Investment Research on MSN9d
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock
The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market value The numerous ...
Fierce Biotech3d
Merck & Co. pens $200M upfront deal for Hengrui's midstage heart disease med
Merck & Co. is handing over $200 million to China’s Hengrui Pharma for a phase 2-stage lipoprotein(a) (Lp(a)) inhibitor.
pharmaphorum5d
Merck puts big bucks behind ADC alliance with China's Kelun
Merck & Co's efforts to diversify its cancer ... a wide-ranging alliance with China's Kelun-Biotech that spans seven antibody-drug conjugates (ADCs) in early development. Merck is paying a ...
BioSpace3d
Merck Commits Nearly $2B for Oral Lipid-Lowering Drug from Chinese Biotech
Merck joins a growing list of companies targeting lipoprotein(a), high levels of which are associated with an elevated risk ...
Fierce Pharma11d
AstraZeneca signs Alteogen deal worth up to $1.35B for subcutaneous cancer drugs despite Merck-Halozyme patent drama
AstraZeneca has signed two deals worth $1.35 billion with Alteogen to develop subcutaneous versions of the British pharma’s ...
Seeking Alpha1mon
Merck's Oncology Strength: Beating Wall Street Again
when Merck entered into an agreement with Daiichi Sankyo (OTCPK:DSKYF) to develop several antibody-drug conjugates. For comparison, and using Seeking Alpha data, Merck's non-GAAP EPS is expected ...